Skylands Capital’s Haemonetics HAE Stock Holding History

Skylands Capital’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.29M	Sell	21,700 -25,925	-54%	-$2.41M	0.3%	80
2026 Q2	$3.57M	Sell	47,625 -18,200	-28%	-$1.17M	0.44%	59
2026 Q1	$3.71M	Buy	65,825 +29,350	+80%	+$1.91M	0.49%	60
2025 Q4	$2.92M	Sell	36,475 -44,894	-55%	-$3.02M	0.4%	71
2025 Q3	$3.97M	Buy	81,369 +53,819	+195%	+$3.33M	0.55%	54
2025 Q2	$2.06M	Sell	27,550 -28,225	-51%	-$1.87M	0.3%	75
2025 Q1	$3.54M	Buy	55,775 +28,600	+105%	+$1.95M	0.51%	57
2024 Q4	$2.12M	Buy	27,175 +3,875	+17%	+$311K	0.3%	75
2024 Q3	$1.87M	Buy	+23,300	New	+$1.88M	0.25%	80

Other funds holding HAE

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Ariel Investments Chicago, Illinois $9.6B AUM 22.21% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

River Road Asset Management Louisville, Kentucky $8.42B AUM 5.65% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Skylands Capital's HAE Position: Q3 2026 in Review

Skylands Capital reduced its Haemonetics (HAE) stake by 54% in Q3 2026, selling an estimated $2.41M and leaving 21,700 shares worth $2.29M. The position accounts for 0.3% of the portfolio, ranked #80.

Skylands Capital first reported a position in HAE in Q3 2024 and has held it in 9 quarters since. The position peaked at $3.97M in Q3 2025. 248 funds tracked by Wall St. Rank hold HAE as of Q3 2026.

Skylands Capital held 21,700 shares of Haemonetics worth $2.29M as of Q3 2026.
Skylands Capital sold 25,925 Haemonetics shares in Q3 2026, an estimated $2.41M.
Haemonetics made up 0.3% of Skylands Capital's portfolio in Q3 2026, its #80 holding.
Skylands Capital first reported a position in Haemonetics in Q3 2024 and has held it in 9 quarters since.
Skylands Capital's Haemonetics position peaked at $3.97M in Q3 2025.
248 funds tracked by Wall St. Rank held Haemonetics as of Q3 2026.

Based on Skylands Capital's 13F filing for Q3 2026, filed 21 Oct 2026.